GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Rifaximin is under clinical development by Nexpharm Korea and currently in Phase I for Irritable Bowel Syndrome.

Rifaximin has already been successfully used in adults with SIBO and IBS. Aim: To assess the SIBO prevalence and symptoms improvement in IBS children after treatment with Rifaximin. Study design ...

Rifaximin is a minimally absorbed antibiotic that is FDA-approved for treatment of travelers' diarrhea and prevention of hepatic encephalopathy. The primary endpoint (patient-reported "adequate ...

Find all the commercial and brand names of generic drug called Rifaximin. This is an invaluable reference resource for healthcare professionals, patients, caregivers and anyone in need of ...

Most Medicare Part D plans and Part C plans that include drug coverage cover rifaximin (Xifaxan) for irritable bowel syndrome with diarrhea (IBS-D) and overt hepatic encephalopathy (HE).